ANSWER: D

Rationale:

The visual symptoms described — flickering zigzag lines and a scintillating scotoma preceding the headache and resolving before head pain begins — are classic migraine aura. Migraine with aura is a WHO MEC Category 4 absolute contraindication to all estrogen-containing methods (combined oral contraceptive, patch, ring) because ethinyl estradiol (EE) produces a multiplicative, not merely additive, increase in ischemic stroke risk when combined with the baseline stroke risk of migraine with aura. The correct action is to discontinue the combined method and transition to a progestin-only option — progestin-only pill, etonogestrel implant, DMPA, or LNG-IUD — all of which are Category 2 (advantages outweigh risks) in migraine with aura because they contain no EE and do not carry the arterial thrombotic risk amplification. Her normal blood pressure and lack of other risk factors do not mitigate the Category 4 status, which is driven by the aura itself.

• Option A: Option A is incorrect because reducing the EE dose to 20 micrograms does not make a combined method acceptable in migraine with aura — the Category 4 contraindication applies to any EE-containing method regardless of dose, because even low-dose EE confers the arterial stroke risk amplification.
• Option B: Option B is incorrect because adding aspirin does not neutralize the EE-mediated stroke risk in migraine with aura and is not an accepted strategy to permit continued combined pill use in a Category 4 condition; the combined method must be discontinued, not supplemented.
• Option C: Option C is incorrect because normal blood pressure and absence of other risk factors do not override the Category 4 designation — migraine with aura is itself the absolute contraindication, and reassuring her to continue the combined pill would expose her to an unacceptable stroke risk.
• Option E: Option E is incorrect because discontinuing all hormonal contraception permanently is unnecessary and not indicated — progestin-only methods are safe (Category 2) in migraine with aura, so she has effective hormonal options; restricting her to barrier methods alone would needlessly deny her reliable contraception.

ANSWER: B

Rationale:

In a woman stabilized on lamotrigine, the priority is to avoid any ethinyl estradiol (EE)-containing method, because EE induces UGT1A4 — the enzyme that glucuronidates lamotrigine — and reduces lamotrigine plasma concentrations by 40 to 65%, risking breakthrough seizures, with rebound toxicity occurring when EE is withdrawn. A progestin-only method (LNG-IUD, etonogestrel implant, or progestin-only pill) contains no EE, does not induce UGT1A4, and therefore does not affect lamotrigine levels, eliminating both the seizure-breakthrough risk and the cyclic rebound. This makes a progestin-only method, particularly a LARC such as the LNG-IUD or implant, the optimal recommendation that protects both seizure control and contraceptive efficacy.

• Option A: Option A is incorrect because even a low 20-microgram EE dose induces UGT1A4 and lowers lamotrigine levels — the interaction is driven by the presence of EE, not by a specific dose threshold, so a low-dose combined pill does not adequately protect seizure control.
• Option C: Option C is incorrect because the estradiol valerate/dienogest pill, although it uses natural estradiol rather than EE, still delivers an estrogen that can affect lamotrigine glucuronidation and is not a reliably interaction-free choice; a progestin-only method is the clearly safer recommendation, and natural estradiol cannot be assumed to have no effect on lamotrigine.
• Option D: Option D is incorrect because depot medroxyprogesterone acetate is not contraindicated in epilepsy — progestin-only methods including DMPA are appropriate, and the claim that only barrier methods are acceptable in women on antiepileptic drugs is wrong; progestin-only hormonal methods are both safe and effective here.
• Option E: Option E is incorrect because the combined vaginal ring delivers ethinyl estradiol that is absorbed systemically and reaches the liver — vaginal administration does not bypass hepatic metabolism in a way that spares UGT1A4 induction, so the ring carries the same lamotrigine interaction as oral combined methods.

ANSWER: A

Rationale:

Rifampin is a potent inducer of CYP3A4 via activation of the pregnane X receptor, and the induction does not end when the drug is stopped. Because enzyme induction works by increasing the synthesis of enzyme protein, the elevated CYP3A4 activity persists for approximately 4 to 6 weeks after the last rifampin dose — the time required for the induced enzyme protein to be cleared and pre-induction CYP3A4 expression to be restored. During this period, ethinyl estradiol and progestin metabolism remains accelerated and the combined pill remains unreliable. The correct counseling is therefore to continue barrier backup contraception for an additional 4 to 6 weeks after the final rifampin dose, not to stop on the day the antibiotic ends.

• Option B: Option B is incorrect because the relevant variable is not how quickly rifampin itself is cleared but how long the induced enzyme remains elevated — even after rifampin is gone, the increased CYP3A4 protein persists for weeks, so stopping backup immediately would leave her at risk of contraceptive failure.
• Option C: Option C is incorrect because rifampin-induced loss of contraceptive efficacy is reversible, not permanent — once the induced enzyme is cleared over 4 to 6 weeks, pill reliability is restored; there is no need to discontinue the pill permanently.
• Option D: Option D is incorrect because a 48-hour washout is far too short — enzyme induction persists for weeks after the inducer is stopped, not hours, so 48 hours would not be sufficient to restore pill reliability.
• Option E: Option E is incorrect because rifampin reduces both ethinyl estradiol (by more than 50%) and progestin levels, and the estrogen component alone does not maintain full contraceptive efficacy — backup contraception was appropriately indicated during and after rifampin therapy.

ANSWER: E

Rationale:

This patient has two features that point decisively to the copper IUD: a BMI of 37 kg/m², at which oral levonorgestrel emergency contraception is unreliable (serum levonorgestrel concentrations become inadequate above approximately BMI 35), and presentation at 96 hours, still within the copper IUD's 5-day window. The copper IUD is the most effective emergency contraceptive available, with a failure rate below 0.1%, and its mechanism — copper ion cytotoxicity to spermatozoa — is entirely independent of body weight, so its efficacy is undiminished at high BMI. It also provides highly effective ongoing contraception, which she desires. This combination of weight-independent efficacy, the 5-day window, and ongoing protection makes the copper IUD clearly the best choice.

• Option A: Option A is incorrect because levonorgestrel 1.5 mg is not reliable at a BMI of 37 — its efficacy is substantially attenuated above approximately BMI 26 and inadequate above approximately BMI 35 — and levonorgestrel's practical window is 72 hours, so at 96 hours it is both outside its optimal window and unreliable at her weight.
• Option B: Option B is incorrect because doubling the levonorgestrel dose is not an evidence-based strategy to overcome high-BMI attenuation — there is no established double-dose regimen that restores reliable efficacy at her BMI, and the copper IUD is the appropriate weight-independent solution.
• Option C: Option C is incorrect because at 96 hours emergency contraception is still indicated — sperm can survive in the reproductive tract for up to 5 days, and the copper IUD can prevent pregnancy from intercourse up to 5 days prior to insertion; reassurance that no intervention is needed would be inappropriate.
• Option D: Option D is incorrect because the Yuzpe regimen (combined estrogen-progestin emergency contraception) is less effective than the copper IUD and than dedicated levonorgestrel or ulipristal regimens, and it is not the most effective option at elevated BMI; it is largely of historical interest and is not the best choice here.

ANSWER: C

Rationale:

On day 13 of a regular 28-day cycle, this patient is at or very near the time of ovulation, meaning her LH surge may already have begun. This cycle timing is decisive for agent selection. Levonorgestrel emergency contraception works only by suppressing the LH surge before it peaks and loses efficacy once the surge is underway. Ulipristal acetate (UPA), a selective progesterone receptor modulator, can still inhibit or delay follicular rupture even after the LH surge has begun — exactly the scenario most likely to result in imminent ovulation. UPA is therefore the pharmacologically preferred agent when a patient presents near ovulation, and at 30 hours she is well within UPA's 120-hour window.

• Option A: Option A is incorrect because levonorgestrel cannot reliably halt an LH surge that has already started — its mechanism is pre-surge suppression, and it loses efficacy precisely at the point of imminent ovulation, which is when this patient presents; the reasoning is the opposite of the pharmacology.
• Option B: Option B is incorrect because cycle timing does affect the relative efficacy of the two agents — their efficacy diverges around the LH surge, where ulipristal acetate retains activity that levonorgestrel lacks, making timing a decisive consideration.
• Option D: Option D is incorrect because ulipristal acetate is not contraindicated within the first 72 hours — it is effective and indicated throughout the 0 to 120-hour window, and it is the preferred agent early in that window when ovulation is imminent, not restricted to the 72 to 120-hour period.
• Option E: Option E is incorrect because advising her to wait and test in 2 weeks abandons the opportunity to prevent pregnancy — at 30 hours after intercourse with ovulation imminent, timely emergency contraception is clearly indicated, and ulipristal acetate is the appropriate choice.

ANSWER: B

Rationale:

Ritonavir-boosted protease inhibitor regimens reduce ethinyl estradiol (EE) exposure by approximately 40 to 50% — despite ritonavir being a potent CYP3A4 inhibitor — because ritonavir induces UGT-mediated EE glucuronidation, and this induction dominates the net effect on EE. As a result, combined hormonal methods are unreliable on a boosted protease inhibitor regimen. The pharmacologically sound approach is therefore twofold: where clinically appropriate from the HIV-treatment standpoint, switching to an integrase strand-transfer inhibitor (INSTI) regimen (which does not alter EE or progestin pharmacokinetics) would make combined hormonal contraception reliable; alternatively, a method unaffected by the interaction — the LNG-IUD (local mechanism) or the copper IUD (non-hormonal) — provides reliable contraception regardless of the antiretroviral regimen. Offering these options respects both her contraceptive preference and her HIV care.

• Option A: Option A is incorrect because ritonavir does not raise ethinyl estradiol levels — its net effect is a reduction in EE exposure through UGT induction, so prescribing a standard combined pill on this regimen would leave her with unreliable contraception.
• Option C: Option C is incorrect because escalating to a 50-microgram EE combined pill to overcome the interaction is not a recommended strategy — it increases estrogen-related risks (VTE, blood pressure) without reliably restoring efficacy, and is inferior to switching the antiretroviral class or using an interaction-independent method.
• Option D: Option D is incorrect because reliable contraception is entirely possible during antiretroviral therapy — the LNG-IUD and copper IUD are unaffected by the interaction, and an INSTI switch restores combined-pill reliability; recommending permanent sterilization as the only option is inappropriate.
• Option E: Option E is incorrect because adding a second protease inhibitor would not protect ethinyl estradiol — the net EE-lowering effect operates through UGT induction, which additional protease inhibitor would not reverse, making this strategy pharmacologically unsound.

ANSWER: A

Rationale:

In the first 6 weeks postpartum, combined hormonal methods are WHO MEC Category 4 in breastfeeding women. Two concerns drive this: the early postpartum period is already a hypercoagulable, elevated-VTE-risk state, and ethinyl estradiol adds further venous thrombotic risk; in addition, there is concern about neonatal exposure to exogenous estrogen through breast milk during the period of neonatal hepatic enzyme immaturity. The appropriate recommendation at 3 weeks postpartum is a progestin-only method — progestin-only pill, etonogestrel implant, or DMPA — which contains no estrogen, does not add to the postpartum VTE risk, and does not adversely affect lactation; these are appropriate now. Her lack of a thrombosis history does not change the Category 4 status, which applies to early-postpartum breastfeeding women as a group.

• Option B: Option B is incorrect because a combined oral contraceptive is not the best choice at 3 weeks postpartum — estrogen does add to the already elevated postpartum thrombotic risk and is Category 4 in this window; the claim that it has no effect on thrombotic risk is wrong.
• Option C: Option C is incorrect because lactational amenorrhea does not provide complete or indefinite protection — it requires strict criteria (exclusive breastfeeding, amenorrhea, within 6 months postpartum) and is not a reliable substitute when she is about to resume intercourse and wants contraception; advising no method would be inappropriate.
• Option D: Option D is incorrect because the postpartum period raises, not lowers, VTE risk — the early puerperium is a recognized hypercoagulable state, so estrogen-containing methods are least safe, not safest, at this time.
• Option E: Option E is incorrect because not all hormonal contraception is contraindicated during breastfeeding — progestin-only methods are safe and appropriate during lactation; restricting her to barrier methods until weaning would needlessly deny her effective contraception.

ANSWER: D

Rationale:

This patient's problem is that the norethindrone 0.35 mg minipill has a strict 3-hour dosing window — because it depends on continuous cervical mucus thickening rather than reliable ovulation suppression, a pill taken more than 3 hours late allows cervical mucus permeability to recover. Two progestin-only solutions address this. The desogestrel 75-microgram pill reliably suppresses ovulation (via etonogestrel) and has a 12-hour missed-pill window, far more forgiving than the norethindrone minipill, while remaining estrogen-free and appropriate for breastfeeding. Alternatively, a long-acting progestin method — the etonogestrel implant or LNG-IUD — removes daily timing from the equation entirely and is the most reliable option for a patient with an unpredictable schedule. Both honor her preference for a progestin-only approach while solving the timing problem.

• Option A: Option A is incorrect because the norethindrone minipill does not have a 12-hour window — it has a strict 3-hour window, which is precisely the source of her problem; reassuring her otherwise would perpetuate her risk of contraceptive failure.
• Option B: Option B is incorrect because taking two minipills when late is not an established corrective strategy and does not reliably restore the cervical mucus barrier after the window has been exceeded — the appropriate solution is a more forgiving formulation or a long-acting method, not double dosing.
• Option C: Option C is incorrect because she is breastfeeding and prefers a progestin-only approach, and a combined oral contraceptive contains estrogen, which is generally avoided in the early breastfeeding period; switching to a combined method would conflict with both her preference and lactation considerations.
• Option E: Option E is incorrect because not all progestin-only pills require a 3-hour window — the desogestrel 75-microgram pill has a 12-hour window owing to reliable ovulation suppression, so she has a more forgiving progestin-only option and is not limited to setting more alarms.

ANSWER: C

Rationale:

Current breast cancer is the one condition in this module for which the usual pattern — combined methods contraindicated, progestin-only methods safe — does not hold. Current breast cancer is a WHO MEC Category 4 absolute contraindication for all hormonal methods, both estrogen-containing and progestin-only, because hormone receptor-positive tumors express both estrogen and progesterone receptors, and exogenous hormones of any class risk stimulating tumor growth or recurrence. The colleague's reasoning that "only estrogen is a problem" is therefore incorrect in this specific setting. The appropriate recommendation is a non-hormonal method, and the copper intrauterine device is the preferred choice: it is highly effective, provides reliable ongoing contraception, and is entirely non-hormonal, working through copper ion cytotoxicity to sperm. Barrier methods and sterilization are other non-hormonal options.

• Option A: Option A is incorrect because progestin-only methods are not safe in current breast cancer — they are Category 4, the same as combined methods, because progesterone receptors in the tumor make progestins a growth risk; the claim that only estrogen is a problem is the specific misconception this question targets.
• Option B: Option B is incorrect because the LNG-IUD, despite its predominantly local action, is still Category 4 in current breast cancer — systemic levonorgestrel exposure, though low, is not considered safe in the presence of an active hormone-sensitive malignancy, so the LNG-IUD is not an acceptable choice here.
• Option D: Option D is incorrect because no ethinyl estradiol dose is acceptable in current breast cancer — combined methods are Category 4 regardless of dose, and there is no "below threshold" estrogen exposure considered safe in an active hormone-sensitive tumor.
• Option E: Option E is incorrect because depot medroxyprogesterone acetate is a systemic progestin and is Category 4 in current breast cancer — its depot delivery does not make it safe, because any systemic progestin exposure risks stimulating a progesterone-receptor-positive tumor.

ANSWER: E

Rationale:

Carbamazepine is a strong inducer of CYP3A4 (via pregnane X receptor and constitutive androstane receptor activation) and accelerates the systemic metabolism of contraceptive steroids, compromising methods that depend on maintaining systemic plasma concentrations. The levonorgestrel-releasing intrauterine device (LNG-IUD) is WHO MEC Category 1 (no restriction) with enzyme-inducing antiepileptic drugs because its contraceptive effect is mediated by high local levonorgestrel concentrations within the endometrium and cervix — many times higher than systemic plasma levels — and these local concentrations are not reduced by systemic enzyme induction. The LNG-IUD therefore offers the most reliable efficacy in this patient without requiring any change to her well-controlled antiepileptic regimen.

• Option A: Option A is incorrect because carbamazepine does affect ethinyl estradiol metabolism — it strongly induces CYP3A4 and reduces EE levels, making combined oral contraceptives Category 3 and unreliable in this setting; the claim of no effect is wrong.
• Option B: Option B is incorrect because the etonogestrel implant is not completely unaffected by enzyme-inducing antiepileptic drugs — its systemic etonogestrel levels can be reduced by CYP3A4 induction, and it is classified Category 2 to 3 with strong inducers, with some guidance recommending against its use; it is not Category 1 like the LNG-IUD.
• Option C: Option C is incorrect because oral progestins are not immune to enzyme induction — the progestin-only pill depends on systemic progestin levels, which are reduced by carbamazepine-induced CYP3A4 activity, compromising its reliability.
• Option D: Option D is incorrect because the combined patch delivers ethinyl estradiol systemically, and transdermal delivery does not bypass systemic CYP3A4 induction — the induced enzymes act on systemically absorbed EE regardless of the route of administration, so the patch is also compromised by carbamazepine.

ANSWER: B

Rationale:

This patient has two features that each independently make combined hormonal methods unsafe and that together make them clearly inappropriate. A blood pressure exceeding 160 mmHg systolic or 100 mmHg diastolic is WHO MEC Category 4 — an absolute contraindication for combined methods — because ethinyl estradiol (EE) raises blood pressure (through hepatic angiotensinogen synthesis) and promotes coagulation and arterial thrombotic risk, producing an unacceptable risk of stroke and myocardial infarction in a patient whose blood pressure is already severely elevated. Her smoking at age 39 compounds the arterial risk. The correct management is to decline the combined method and recommend a non-estrogen option — a progestin-only method or the copper IUD — and, importantly, to evaluate and treat her newly identified severe hypertension, which is a significant finding in its own right.

• Option A: Option A is incorrect because a low 20-microgram EE dose does not offset severe hypertension and smoking — combined methods are Category 4 at her blood pressure regardless of EE dose, because even low-dose EE adds arterial thrombotic risk in this setting.
• Option C: Option C is incorrect because prescribing the combined pill and rechecking in 3 months would expose her to an unacceptable arterial thrombotic risk during that interval — her blood pressure already exceeds the Category 4 threshold, so the combined method should not be started at all.
• Option D: Option D is incorrect because the combined patch contains ethinyl estradiol absorbed systemically and carries the same blood-pressure and thrombotic risks as the oral pill — transdermal EE is not free of these effects, and the patch is also Category 4 in severe hypertension.
• Option E: Option E is incorrect because adding an antihypertensive does not immediately remove the contraindication — uncontrolled severe hypertension is Category 4, and even adequately controlled hypertension remains Category 3 for combined methods; starting an EE-containing method concurrently with beginning blood-pressure treatment is not appropriate, and a non-estrogen method is the correct choice.